LBRX
LB Pharmaceuticals Inc Common Stock
NASDAQ · Healthcare · Biotechnology · US
$49.34
+3.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 179.0K | — | — | — | — |
| Gross Profit | (179.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 69.7M | 16.7M | 51.2M | 7.8M | 1.3M |
| SG&A Expense | 25.3M | 13.7M | 13.7M | 3.5M | 1.5M |
| General & Admin Expense | 8.2M | 13.7M | 13.7M | 3.5M | 1.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 95.0M | 30.4M | 64.8M | 11.4M | 2.8M |
| Cost and Expenses | 95.1M | 30.4M | 64.8M | 11.4M | 2.8M |
| Operating Income (EBIT) | (95.1M) | (30.4M) | (64.8M) | (11.4M) | (2.8M) |
| Non-Operating | |||||
| Interest Income | 9.3M | 3.9M | 1.7M | 811.0K | 73.0K |
| Interest Expense | — | — | — | 4.8M | 2.2M |
| Net Interest Income | 9.3M | 3.9M | 1.7M | (4.0M) | (2.1M) |
| Other Non-Op Income/Expense | 9.5M | 5.2M | 1.7M | 5.1M | (11.5M) |
| Non-Operating Income (excl Interest) | (7.1M) | (5.2M) | (1.7M) | (9.9M) | 9.4M |
| EBT (Pre-Tax Income) | (85.7M) | (25.2M) | (63.1M) | (6.3M) | (14.3M) |
| Income Tax Expense | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K |
| Bottom Line | |||||
| Net Income | (85.7M) | (25.2M) | (63.1M) | (6.3M) | (14.3M) |
| Earnings from Cont. Ops | (85.7M) | (25.2M) | (63.1M) | (6.3M) | (14.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (85.7M) | (25.2M) | (63.1M) | (6.3M) | (14.3M) |
| Per Share | |||||
| Basic EPS | ($2.97) | ($1.00) | ($17.83) | ($1.77) | ($4.05) |
| Diluted EPS | ($2.97) | ($1.00) | ($17.83) | ($1.77) | ($4.05) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 30.1M | 25.3M | 3.5M | 3.5M | 3.5M |
| Diluted Shares Outstanding | 30.1M | 25.3M | 3.5M | 3.5M | 3.5M |
| Profitability Metrics | |||||
| EBITDA | (87.7M) | (24.9M) | (63.0M) | (1.4M) | (12.2M) |
| D&A | 345.0K | 321.0K | 91.0K | 4.0K | 2.0K |
| EBIT | (88.0M) | (25.2M) | (63.1M) | (1.4M) | (12.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026